Management Team
|
Oren M. Becker, PhD |
More than 19 years of leadership and management experience in pharmaceutical drug discovery & development. Since founding Dynamix Pharmaceuticals in 2009, Dr. Becker serves as its President and CEO. Prior to that Dr. Becker was co-Founder and CSO of Predix Pharmaceuticals Inc., which merged with Epix Pharmaceuticals Inc. (NASDAQ) for $125M, and signed $1.5B worth deals with GSK and Amgen. Former CSO of Epix Pharmaceuticals. Led the discovery of five drugs in clinical development. Formerly a professor at Tel-Aviv University and a visiting professor at Harvard University. Education: Hebrew Univ. (PhD), Harvard Univ.(postdoc). |
| Yossi Bar-On, CPA Chief Financial Officer |
Mr. Bar-On joined Dynamix from its inception in early 2009, as a member of the Executive Team, working to build the company. Prior to joining Dynamix, Mr. Bar-On served as the CFO of Mirage Innovations, a developer and manufacturer company of cutting-edge Personal Video Displays, and as the CFO of Tegrity (acquired by McGraw-Hill Education), an award-winning lecture capture solutions company. As Dynamix's CFO, Mr. Bar-On holds responsibility for a wide variety of core functions at Dynamix, including Finance, Operations, Human Resources and Organizational Development functions. Mr. Bar-On received a B.A. in Accounting and Economics from The Hebrew University. Mr. Bar-On is a current member of the Israeli Institute of Certified Public Accountants. |
| Vered Behar, PhD, MBA VP Biology |
Dr. Behar has more than 11 years experience in the Pharma and Biotech industries, both in the US and in Israel. Her multi-disciplinary background covers diverse disciplines of cell and molecular biology, pharmacology, and pre-clinical testing. She joined Dynamix from its inception in early 2009. Prior to Dynamix, Dr. Behar worked with top American VC firms as a scout in Israel, and held various leadership positions at Quantomix, a life sciences tool company, where she worked for 6 years. In her latest position as Chief Scientist of Quantomix, she was responsible for partnering with Pharmaceutical companies. Before returning to Israel, Vered was a researcher at Wyeth Pharmaceuticals (now Pfizer) in Cambridge, MA. Dr. Behar received her PhD from Harvard University in Medical Sciences and her MBA from the Hebrew University in Jerusalem, Israel. She published extensively in leading peer-reviewed journals and received various honors and awards. |
| Avihai Yacovan, PhD VP Chemistry |
More than 16 years of pharmaceutical R&D and industrial experience. Prior to joining Dynamix Dr. Yacovan served as VP Chemistry of Aminolab-Pharma Ltd, responsible for the medicinal chemistry group, and project leader. Before that he served as Senior Director of Chemistry and Process Development at Pharmos (NASDQ:PARS), a drug discovery and development company, managing the medicinal chemistry research group in design and synthesis of novel compounds, as well as improving their physiochemical profile identifying drug candidates and managing the scale-up activities of the chosen drug candidates at clinical and pre-clinical stages. During his tenure he was involved in discovering the drug Cannabinor, which reached Phase 2 clinical studies for pain, as well as additional preclinical compounds. Before that Dr. Yacovan was a Project leader at Agan Chemical Manufacturers Ltd. Dr. Yacovan hold as PhD in chemistry from Bar-Ilan University (PhD). |
| Ofer Shpilberg, MD, MPH Director, Clinical Research |
Head, Hematology Division, Davidoff Cancer Center & Beilinson Hospital, Israel; U. Pittsburgh; Soroka Medical Center; Sheba Medical Center. |
Management Team